|出版日期||內容資訊||英文 71 Pages
本報告以心臟標記市場為焦點，提供心臟標記市場評估，使用生物標記的心臟疾病 (CVD) 檢驗的估計、競爭分析，全球心血管疾病生物標記診斷市場預測，心臟疾病的主要的IVD標記，心臟疾病的主要生物標記、生物標記面板與其開發/銷售企業，主要的脂質生物標記與其開發/銷售企業等系統性資訊。
Biomarkers are biological or biochemical molecules, or genetic changes, or other characteristics that can be measured, and that indicate or predict a condition, risk, or likely response. Biomarkers can be used for a range of diagnostic applications including predicting disease risk, diagnosis, predicting prognosis, identifying appropriate therapy for an individual, monitoring disease or for return of a disease, and other applications. With the incidence of cardiovascular disease increasing greatly, cardiac markers and cardiovascular biomarkers are in huge demand. Cardiac Markers provides market assessment, estimate and competitive analysis for tests for cardiovascular disease (CVD) that use biomarkers, including:
Physicians use cardiac markers (CK-MB, troponin I, troponin T, myoglobin, brain natriuretic peptide (BNP), proBNP, high sensitive C-reactive protein (hsCRP), and homocysteine) and cardiovascular biomarkers in two ways: acute care to diagnose a cardiac event in a hospital emergency room (acute care) or chronic care to evaluate the risk of a cardiovascular event occurring and to monitor patients with a cardiovascular disease. The traditional markers - CK-MB, troponin and myoglobin - were used in acute care and tests such as cholesterol were used to evaluate risk.
In the past few years cardiac markers have been revitalized with tests such as myeloperoxidase (MPO) brain natriuretic peptide (BNP), proBNP becoming part of the acute care test menu and tests such as high sensitive C-reactive protein (hsCRP), high sensitive troponin, homocysteine, Fatty Acid Binding Protein (FABP), Glycogen Phosphorylase isoenzyme BB (GPBB), urinary albumin, S-100 protein and hemoglobin A1c (hbA1c) now part of the risk evaluation tool box.
Cardiac Markers reviews the progression of cardiac diagnostic technologies and notes some trends in test strategies as well, including:
As diagnostic companies strive to provide platforms allowing for quick yet accurate diagnoses of patients, there is growing opportunity in the cardiac marker market. In the U.S., the Affordable Care Act (ACA), which is designed to advance healthcare accessibility, has helped to drive the market. The ACA encourages a shift toward payment based on the value of care.
There are currently a number of companies developing or marketing cardiac markers and cardiovascular biomarkers. This report contains profiles of many of the top competitors, including:
The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics and personalized medicine.